imatinib mesylate has been researched along with Niemann-Pick Disease, Type C in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alvarez, AR; Amigo, J; Bronfman, FC; Cancino, GI; Castro, J; Klein, A; Mosqueira, M; Vargas, LM; YĆ©venes, LF; Zanlungo, S | 1 |
1 other study(ies) available for imatinib mesylate and Niemann-Pick Disease, Type C
Article | Year |
---|---|
Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease.
Topics: Animals; Apoptosis; Benzamides; Cell Survival; Cerebellar Cortex; Disease Models, Animal; DNA-Binding Proteins; Gene Expression; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mice; Mice, Knockout; Motor Activity; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C; Nuclear Proteins; Piperazines; Proteins; Proto-Oncogene Proteins c-abl; Purkinje Cells; Pyrimidines; RNA, Messenger; Tumor Protein p73; Tumor Suppressor Proteins | 2008 |